Reduced expression of insulin-like growth factor binding protein-3 and its promoter hypermethylation in human hepatocellular carcinoma

Tadashi Hanafusa; Yasuhiro Yumoto; Kazuhiro Nouso; Harushige Nakatsukasa; Toru Onishi; Tatsuya Fujikawa; Mayumi Taniyama; Shinichiro Nakamura; Masayuki Uemura; Yoshitaka Takuma; Eiichiro Yumoto; Toshihiro Higashi; Takao Tsuji

doi:10.1016/S0304-3835(01)00736-4

Reduced expression of insulin-like growth factor binding protein-3 and its promoter hypermethylation in human hepatocellular carcinoma

Tadashi Hanafusa, Yasuhiro Yumoto, Kazuhiro Nouso, Harushige Nakatsukasa, Toru Onishi, Tatsuya Fujikawa, Mayumi Taniyama, Shinichiro Nakamura, Masayuki Uemura, Yoshitaka Takuma, Eiichiro Yumoto, Toshihiro Higashi, Takao Tsuji

中性子医療研究センター

研究成果 › 査読

111 被引用数 (Scopus)

抄録

Insulin-like growth factor binding protein-3 (IGFBP-3) is postulated to be a mediator of growth suppression signals. Reduced expression of the IGFBP-3 was observed in nine out of 12 human hepatocellular carcinomas (HCC) (75%). Promoter hypermethylation of the IGFBP-3 was detected in four out of 12 HCCs (33%) although mutations were not identified. The expression of IGFBP-3 was restored by the demethylating agent 5-aza-2′-deoxycytidine in HCC cell line with promoter hypermethylation (HepG2). As IGFBP-3 functions like a tumor suppressor gene, it may be used as a therapeutic target for HCC.

本文言語	English
ページ（範囲）	149-158
ページ数	10
ジャーナル	Cancer Letters
巻	176
号	2
DOI	https://doi.org/10.1016/S0304-3835(01)00736-4
出版ステータス	Published - 2月 25 2002

ASJC Scopus subject areas

腫瘍学
癌研究

UN SDG

この成果は、次の持続可能な開発目標に貢献しています

文献へのアクセス

10.1016/S0304-3835(01)00736-4

他のファイルとリンク

フィンガープリント

「Reduced expression of insulin-like growth factor binding protein-3 and its promoter hypermethylation in human hepatocellular carcinoma」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル

Hanafusa, T., Yumoto, Y., Nouso, K., Nakatsukasa, H., Onishi, T., Fujikawa, T., Taniyama, M., Nakamura, S., Uemura, M., Takuma, Y., Yumoto, E., Higashi, T., & Tsuji, T. (2002). Reduced expression of insulin-like growth factor binding protein-3 and its promoter hypermethylation in human hepatocellular carcinoma. Cancer Letters, 176(2), 149-158. https://doi.org/10.1016/S0304-3835(01)00736-4

Hanafusa, T, Yumoto, Y, Nouso, K, Nakatsukasa, H, Onishi, T, Fujikawa, T, Taniyama, M, Nakamura, S, Uemura, M, Takuma, Y, Yumoto, E, Higashi, T & Tsuji, T 2002, 'Reduced expression of insulin-like growth factor binding protein-3 and its promoter hypermethylation in human hepatocellular carcinoma', Cancer Letters, vol. 176, no. 2, pp. 149-158. https://doi.org/10.1016/S0304-3835(01)00736-4

@article{b35d21a92b6848d3ad3f12ed289453ff,

title = "Reduced expression of insulin-like growth factor binding protein-3 and its promoter hypermethylation in human hepatocellular carcinoma",

abstract = "Insulin-like growth factor binding protein-3 (IGFBP-3) is postulated to be a mediator of growth suppression signals. Reduced expression of the IGFBP-3 was observed in nine out of 12 human hepatocellular carcinomas (HCC) (75%). Promoter hypermethylation of the IGFBP-3 was detected in four out of 12 HCCs (33%) although mutations were not identified. The expression of IGFBP-3 was restored by the demethylating agent 5-aza-2′-deoxycytidine in HCC cell line with promoter hypermethylation (HepG2). As IGFBP-3 functions like a tumor suppressor gene, it may be used as a therapeutic target for HCC.",

keywords = "Hepatocellular carcinoma, Hypermethylation, Insulin-like growth factor binding protein-3, Mannose 6-phosphate/insulin-like growth factor 2 receptor, cDNA microarray",

author = "Tadashi Hanafusa and Yasuhiro Yumoto and Kazuhiro Nouso and Harushige Nakatsukasa and Toru Onishi and Tatsuya Fujikawa and Mayumi Taniyama and Shinichiro Nakamura and Masayuki Uemura and Yoshitaka Takuma and Eiichiro Yumoto and Toshihiro Higashi and Takao Tsuji",

note = "Funding Information: We are grateful to T. Mimura (Okayama Saiseikai General Hospital, Okayama, Japan), T. Kurokawa (Saiseikai Imabari Hospital, Imabari, Japan), for their support in obtaining materials and Y. Isomoto (Central Research Laboratory, Okayama University Medical School) for his technical support. We also thank Y. Iwasaki (First Department of Internal Medicine, Okayama Medical School) for his valuable suggestion to this work. This work was supported in part by grants-in-aid for Scientific Research from the Ministry of Education, Science and Culture of Japan (#09770359, #11770273).",

year = "2002",

month = feb,

day = "25",

doi = "10.1016/S0304-3835(01)00736-4",

language = "English",

volume = "176",

pages = "149--158",

journal = "Cancer Letters",

issn = "0304-3835",

publisher = "Elsevier Ireland Ltd",

number = "2",

}

TY - JOUR

T1 - Reduced expression of insulin-like growth factor binding protein-3 and its promoter hypermethylation in human hepatocellular carcinoma

AU - Hanafusa, Tadashi

AU - Yumoto, Yasuhiro

AU - Nouso, Kazuhiro

AU - Nakatsukasa, Harushige

AU - Onishi, Toru

AU - Fujikawa, Tatsuya

AU - Taniyama, Mayumi

AU - Nakamura, Shinichiro

AU - Uemura, Masayuki

AU - Takuma, Yoshitaka

AU - Yumoto, Eiichiro

AU - Higashi, Toshihiro

AU - Tsuji, Takao

N1 - Funding Information: We are grateful to T. Mimura (Okayama Saiseikai General Hospital, Okayama, Japan), T. Kurokawa (Saiseikai Imabari Hospital, Imabari, Japan), for their support in obtaining materials and Y. Isomoto (Central Research Laboratory, Okayama University Medical School) for his technical support. We also thank Y. Iwasaki (First Department of Internal Medicine, Okayama Medical School) for his valuable suggestion to this work. This work was supported in part by grants-in-aid for Scientific Research from the Ministry of Education, Science and Culture of Japan (#09770359, #11770273).

PY - 2002/2/25

Y1 - 2002/2/25

N2 - Insulin-like growth factor binding protein-3 (IGFBP-3) is postulated to be a mediator of growth suppression signals. Reduced expression of the IGFBP-3 was observed in nine out of 12 human hepatocellular carcinomas (HCC) (75%). Promoter hypermethylation of the IGFBP-3 was detected in four out of 12 HCCs (33%) although mutations were not identified. The expression of IGFBP-3 was restored by the demethylating agent 5-aza-2′-deoxycytidine in HCC cell line with promoter hypermethylation (HepG2). As IGFBP-3 functions like a tumor suppressor gene, it may be used as a therapeutic target for HCC.

AB - Insulin-like growth factor binding protein-3 (IGFBP-3) is postulated to be a mediator of growth suppression signals. Reduced expression of the IGFBP-3 was observed in nine out of 12 human hepatocellular carcinomas (HCC) (75%). Promoter hypermethylation of the IGFBP-3 was detected in four out of 12 HCCs (33%) although mutations were not identified. The expression of IGFBP-3 was restored by the demethylating agent 5-aza-2′-deoxycytidine in HCC cell line with promoter hypermethylation (HepG2). As IGFBP-3 functions like a tumor suppressor gene, it may be used as a therapeutic target for HCC.

KW - Hepatocellular carcinoma

KW - Hypermethylation

KW - Insulin-like growth factor binding protein-3

KW - Mannose 6-phosphate/insulin-like growth factor 2 receptor

KW - cDNA microarray

UR - http://www.scopus.com/inward/record.url?scp=18244401685&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=18244401685&partnerID=8YFLogxK

U2 - 10.1016/S0304-3835(01)00736-4

DO - 10.1016/S0304-3835(01)00736-4

M3 - Article

C2 - 11804742

AN - SCOPUS:18244401685

SN - 0304-3835

VL - 176

SP - 149

EP - 158

JO - Cancer Letters

JF - Cancer Letters

IS - 2

ER -